nach oben

HNO

Erschienen in:

01.08.2015 | CME

Maligne Melanome im Kopf-Hals-Bereich

Teil 2: Therapie

verfasst von: Prof. Dr. C. Pföhler, T. Vogt, C.S.L. Müller

Erschienen in: HNO | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Exzision maligner Melanome muss im Kopf-Hals-Bereich insbesondere im Hinblick auf die notwendigen Sicherheitsabstände oft an die anatomischen Gegebenheiten angepasst werden. Bei Vorliegen dickerer Primärtumoren bzw. nach vollständiger Entfernung etwaiger lokoregionärer Lymphknotenmetastasen kann eine adjuvante Therapie mit Interferon-α durchgeführt werden, ggf. ist auch eine adjuvante Strahlentherapie indiziert. Sofern eine inoperable Lymphknoten- oder Fernmetastasierung aufgetreten ist, besteht die Notwendigkeit zur systemischen Therapie. Hierfür stehen neben den etablierten Mono- und Polychemotherapien bei Vorhandensein spezifischer Mutationen im Tumorgewebe auch zielgerichtete Therapien mit z. B. BRAF-Inhibitoren (Vemurafenib, Dabrafenib), Mitogen-aktivierte Proteinkinasen (MEK)-Inhibitoren (Trametinib, Binimetinib und Cobimetinib) und Kinaseinhibitoren (Imatinib, Sunitinib, Nilotinib, Dasatinib) zur Verfügung.

Tran KT, Wright NA, Cockerell CJ (2008) Biopsy of the pigmented lesion – when and how. J Am Acad Dermatol 59:852–871PubMed

Sladden MJ, Balch C, Barzilai DA, Berg D, Freiman A, Handiside T, Hollis S, Lens MB, Thompson JF (2009) Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev 7(4):CD004835

Brown CD, Zitelli JA (1995) The prognosis and treatment of true local cutaneous recurrent malignant melanoma. Dermatol Surg 21:285–290PubMed

Cohen L, Cohen MH, Kirkwood C, Russell NC (2007) Discussing complementary therapies in an oncology setting. J Soc Integr Oncol 5:18–24PubMed

Dawn ME, Dawn AG, Miller SJ (2007) Mohs surgery for the treatment of melanoma in situ: a review. Dermatol Surg 33:395–402PubMed

Loser C, Rompel R, Breuninger H, Mohrle M, Hafner HM, Kunte C, Hassel J, Hohenleutner U, Podda M, Sebastian G, Hafner J, Konz B, Kaufmann R (2010) German Society for D. Microscopically controlled surgery (MCS). J Dtsch Dermatol Ges 8:920–925PubMed

Dong XD, Tyler D, Johnson JL, DeMatos P, Seigler HF (2000) Analysis of prognosis and disease progression after local recurrence of melanoma. Cancer 88:1063–1071PubMed

Lund VJ, Stammberger H, Nicolai P, Castelnuovo P, Beal T, Beham A, Bernal-Sprekelsen M, Braun H, Cappabianca P, Carrau R, Cavallo L, Clarici G, Draf W, Esposito F, Fernandez-Miranda J, Fokkens W, Gardner P, Gellner V, Hellquist H, Hermann P, Hosemann W, Howard D, Jones N, Jorissen M, Kassam A, Kelly D, Kurschel-Lackner S, Leong S, McLaughlin N, Maroldi R, Minovi A, Mokry M, Onerci M, Ong YK, Prevedello D, Saleh H, Sehti DS, Simmen D, Snyderman C, Solares A, Spittle M, Stamm A, Tomazic P, Trimarchi M, Unger F, Wormald PJ, Zanation A (2010) European Rhinologic Society Advisory Board on Endoscopic Techniques in the Management of Nose PS, Skull Base T. European position paper on endoscopic management of tumours of the nose, paranasal sinuses and skull base. Rhinol Suppl 22:1–143PubMed

Lopez F, Rodrigo JP, Cardesa A, Triantafyllou A, Devaney KO, Mendenhall WM, Haigentz M, Strojan P, Pellitteri PK, Bradford CR, Shaha AR, Hunt JL, de Bree R, Takes RP, Rinaldo A, Ferlito A (2014) Update on primary head and neck mucosal melanoma. Head Neck. doi:10.1002/hed.23872

10.

Fadaki N, Li R, Parrett B, Sanders G, Thummala S, Martineau L, Cardona-Huerta S, Miranda S, Cheng ST, Miller JR 3rd, Singer M, Cleaver JE, Kashani-Sabet M, Leong SP (2013) Is head and neck melanoma different from trunk and extremity melanomas with respect to sentinel lymph node status and clinical outcome? Ann Surg Oncol 20:3089–3097PubMed

11.

Krengli M, Masini L, Kaanders JH, Maingon P, Oei SB, Zouhair A, Ozyar E, Roelandts M, Amichetti M, Bosset M, Mirimanoff RO (2006) Radiotherapy in the treatment of mucosal melanoma of the upper aerodigestive tract: analysis of 74 cases. A rare cancer network study. Int J Radiat Oncol Biol Phys 65:751–759PubMed

12.

Medina JE, Ferlito A, Pellitteri PK, Shaha AR, Khafif A, Devaney KO, Fisher SR, O’Brien CJ, Byers RM, Robbins KT, Pitman KT, Rinaldo A (2003) Current management of mucosal melanoma of the head and neck. J Surg Oncol 83:116–122PubMed

13.

Kunte C, Geimer T, Baumert J, Konz B, Volkenandt M, Flaig M, Ruzicka T, Berking C, Schmid-Wendtner MH (2010) Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1049 patients with cutaneous melanoma. Melanoma Res 20:330–337PubMed

14.

Mays MP, Martin RC, Burton A, Ginter B, Edwards MJ, Reintgen DS, Ross MI, Urist MM, Stromberg AJ, McMasters KM, Scoggins CR (2010) Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy? Cancer 116:1535–1544PubMed

15.

McMasters KM (2001) The sunbelt melanoma trial. Ann Surg Oncol 8:41S–43SPubMed

16.

McMasters KM, Wong SL, Edwards MJ, Ross MI, Chao C, Noyes RD, Viar V, Cerrito PB, Reintgen DS (2001) Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery 130:151–156PubMed

17.

Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Puleo CA, Coventry BJ, Kashani-Sabet M, Smithers BM, Paul E, Kraybill WG, McKinnon JG, Wang HJ, Elashoff R, Faries MB, Group M (2014) Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 370:599–609PubMedCentralPubMed

18.

Testori A, De Salvo GL, Montesco MC, Trifiro G, Mocellin S, Landi G, Macripo G, Carcoforo P, Ricotti G, Giudice G, Picciotto F, Donner D, Di Filippo F, Soteldo J, Casara D, Schiavon M, Vecchiato A, Pasquali S, Baldini F, Mazzarol G, Rossi CR, Italian Melanoma I (2009) Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI). Ann Surg Oncol 16:2018–2027PubMed

19.

Valsecchi ME, Silbermins D, de Rosa N, Wong SL, Lyman GH (2011) Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol 29:1479–1487PubMed

20.

Warycha MA, Zakrzewski J, Ni Q, Shapiro RL, Berman RS, Pavlick AC, Polsky D, Mazumdar M, Osman I (2009) Meta-analysis of sentinel lymph node positivity in thin melanoma (&or=1 mm). Cancer 115:869–879PubMedCentralPubMed

21.

Kupferman ME, Kubik MW, Bradford CR, Civantos FJ, Devaney KO, Medina JE, Rinaldo A, Stoeckli SJ, Takes RP, Ferlito A (2014) The role of sentinel lymph node biopsy for thin cutaneous melanomas of the head and neck. Am J Otolaryngol 35:226–232PubMed

22.

Sperry SM, Charlton ME, Pagedar NA (2014) Association of sentinel lymph node biopsy with survival for head and neck melanoma: survival analysis using the SEER database. JAMA Otolaryngol – Head Neck Surg 140:1101–1109PubMed

23.

Kretschmer L, Thoms KM, Peeters S, Haenssle H, Bertsch HP, Emmert S (2008) Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonodectomy versus complete regional lymph node dissection. Melanoma Res 18:16–21PubMed

24.

Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Wang HJ (2005) Multicenter Selective Lymphadenectomy Trial G. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 242:302–311 (discussion 11–3)PubMedCentralPubMed

25.

Roaten JB, Pearlman N, Gonzalez R, Gonzalez R, McCarter MD (2005) Identifying risk factors for complications following sentinel lymph node biopsy for melanoma. Arch Surgery 140:85–89

26.

Gutzmer R, Satzger I, Thoms KM, Volker B, Mitteldorf C, Kapp A, Bertsch HP, Kretschmer L (2008) Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas. J Dtsch Dermatol Ges 6:198–203PubMed

27.

Leong SP (2011) Role of selective sentinel lymph node dissection in head and neck melanoma. J Surg Oncol 104:361–368PubMed

28.

Paek SC, Griffith KA, Johnson TM, Sondak VK, Wong SL, Chang AE, Cimmino VM, Lowe L, Bradford CR, Rees RS, Sabel MS (2007) The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer 109:100–108PubMed

29.

Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ, Cochran AJ (1992) Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surgery 127:392–399

30.

Baptista P, Garcia Velloso MJ, Salvinelli F, Casale M (2008) Radioguided surgical strategy in mucosal melanoma of the nasal cavity. Clin Nucl Med 33:14–18PubMed

31.

Starek I, Koranda P, Benes P (2006) Sentinel lymph node biopsy: A new perspective in head and neck mucosal melanoma? Melanoma Res 16:423–427PubMed

32.

Lens MB, Dawes M, Goodacre T, Newton-Bishop JA (2002) Elective lymph node dissection in patients with melanoma: systematic review and meta-analysis of randomized controlled trials. Arch Surgery 137:458–461

33.

Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D, Dippel E, Eigentler T, Feyer P, Follmann M, Frerich B, Ganten MK, Gartner J, Gutzmer R, Hassel J, Hauschild A, Hohenberger P, Hubner J, Kaatz M, Kleeberg UR, Kolbl O, Kortmann RD, Krause-Bergmann A, Kurschat P, Leiter U, Link H, Loquai C, Loser C, Mackensen A, Meier F, Mohr P, Mohrle M, Nashan D, Reske S, Rose C, Sander C, Satzger I, Schiller M, Schlemmer HP, Strittmatter G, Sunderkotter C, Swoboda L, Trefzer U, Voltz R, Vordermark D, Weichenthal M, Werner A, Wesselmann S, Weyergraf AJ, Wick W, Garbe C, Schadendorf D, German Dermatological S, DermatologicCooperative Oncology G. (2013) Malignant melanoma S3-guideline „diagnosis, therapy and follow-up of melanoma“. J Dtsch Dermatol Ges 11(Suppl 6):1–116 (1–26)PubMed

34.

Zitsch RP 3rd, Roberts GD, Smith RB (1999) Recurrent cutaneous melanoma of the head and neck. Otolaryngol – Head Neck Surg 120:391–393PubMed

35.

Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr., Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199–6206PubMedCentralPubMed

36.

Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, Cascinelli N, Cochran AJ, Coit DG, Eggermont AM, Johnson T, Kirkwood JM, Leong SP, McMasters KM, Mihm MC Jr., Morton DL, Ross MI, Sondak VK (2010) Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28:2452–2459PubMedCentralPubMed

37.

Satzger I, Volker B, Meier A, Kapp A, Gutzmer R (2008) Criteria in sentinel lymph nodes of melanoma patients that predict involvement of nonsentinel lymph nodes. Ann Surg Oncol 15:1723–1732PubMed

38.

van der Ploeg AP, van Akkooi AC, Rutkowski P, Nowecki ZI, Michej W, Mitra A, Newton-Bishop JA, Cook M, van der Ploeg IM, Nieweg OE, van den Hout MF, van Leeuwen PA, Voit CA, Cataldo F, Testori A, Robert C, Hoekstra HJ, Verhoef C, Spatz A, Eggermont AM (2011) Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol 29:2206–2214PubMed

39.

Stoffels I, Boy C, Poppel T, Kuhn J, Klotgen K, Dissemond J, Schadendorf D, Klode J (2012) Association between sentinel lymph node excision with or without preoperative SPECT/CT and metastatic node detection and disease-free survival in melanoma. Jama 308:1007–1014PubMed

40.

Wiener M, Uren RF, Thompson JF (2014) Lymphatic drainage patterns from primary cutaneous tumours of the forehead: refining the recommendations for selective neck dissection. J Plast Reconstr Aesthetic Surg 67:1038–1044

41.

O’Brien CJ, Coates AS, Petersen-Schaefer K, Shannon K, Thompson JF, Milton GW, McCarthy WH (1991) Experience with 998 cutaneous melanomas of the head and neck over 30 years. Am J Surg 162:310–314PubMed

42.

O’Brien CJ, Gianoutsos MP, Morgan MJ (1992) Neck dissection for cutaneous malignant melanoma. World J Surg 16:222–226PubMed

43.

Byers RM (1998) Treatment of the neck in melanoma. Otolaryngol Clin N Am 31:833–839

44.

Schmalbach CE, Johnson TM, Bradford CR (2006) The management of head and neck melanoma. Curr Probl Surg 43:781–835PubMed

45.

Robbins KT, Clayman G, Levine PA, Medina J, Sessions R, Shaha A, Som P, Wolf GT, American H, Neck S, American Academy of O-H, Neck S (2002) Neck dissection classification update: revisions proposed by the american head and neck society and the american academy of otolaryngology-head and neck surgery. Arch Otolaryngol – Head Neck Surg 128:751–758PubMed

46.

Robbins KT, Medina JE, Wolfe GT, Levine PA, Sessions RB, Pruet CW (1991) Standardizing neck dissection terminology. Official report of the academy’s committee for head and neck surgery and oncology. Arch Otolaryngol – Head Neck Surg 117:601–605PubMed

47.

Andersen PS, Chakera AH, Thamsborg AK, Kolle SF, Schmidt G, Klyver H, Drzewiecki KT (2014) Recurrence and survival after neck dissections in cutaneous head and neck melanoma. Dan Med J 61:A4953PubMed

48.

Geltzeiler M, Monroe M, Givi B, Vetto J, Andersen P, Gross N (2014) Regional control of head and neck melanoma with selective neck dissection. JAMA Otolaryngol – Head Neck Surg 140:1014–1018PubMed

49.

Mack LA, McKinnon JG (2004) Controversies in the management of metastatic melanoma to regional lymphatic basins. J Surg Oncol 86:189–199PubMed

50.

Thom JJ, Moore EJ, Price DL, Kasperbauer JL, Starkman SJ, Olsen KD (2014) The role of total parotidectomy for metastatic cutaneous squamous cell carcinoma and malignant melanoma. JAMA Otolaryngol – Head Neck Surg. doi:10.1001/jamaoto.2014.352

51.

White N, Yap LH, Srivastava S (2009) Lymphadenectomy for melanoma in the clinically N1 neck: radical, modified radical, or selective? J Craniofacial Surg 20:385–388

52.

Serpell JW, Carne PW, Bailey M (2003) Radical lymph node dissection for melanoma. ANZ J Surg 73:294–299PubMed

53.

van Akkooi AC, Bouwhuis MG, de Wilt JH, Kliffen M, Schmitz PI, Eggermont AM (2007) Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma. Br J Surg 94:1293–1299PubMed

54.

Agrawal S, Kane JM 3rd, Guadagnolo BA, Kraybill WG, Ballo MT (2009) The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer 115:5836–5844PubMed

55.

Bibault JE, Dewas S, Mirabel X, Mortier L, Penel N, Vanseymortier L, Lartigau E (2011) Adjuvant radiation therapy in metastatic lymph nodes from melanoma. Radiat Oncol 6:12PubMedCentralPubMed

56.

Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF (2012) Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 13:589–597PubMed

57.

Creagan ET, Cupps RE, Ivins JC, Pritchard DJ, Sim FH, Soule EH, O’Fallon JR (1978) Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, prospective study. Cancer 42:2206–2210PubMed

58.

Gojkovic-Horvat A, Jancar B, Blas M, Zumer B, Karner K, Hocevar M, Strojan P (2012) Adjuvant radiotherapy for palpable melanoma metastases to the groin: when to irradiate? Int J Radiat Oncol Biol Phys 83:310–316PubMed

59.

Hamming-Vrieze O, Balm AJ, Heemsbergen WD, Hooft van Huysduynen T, Rasch CR (2009) Regional control of melanoma neck node metastasis after selective neck dissection with or without adjuvant radiotherapy. Arch Otolaryngol – Head Neck Surg 135:795–800PubMed

60.

Moncrieff MD, Martin R, O’Brien CJ, Shannon KF, Clark JR, Gao K, McCarthy WM, Thompson JF (2008) Adjuvant postoperative radiotherapy to the cervical lymph nodes in cutaneous melanoma: is there any benefit for high-risk patients? Ann Surg Oncol 15:3022–3027PubMed

61.

O’Brien CJ, Petersen-Schaefer K, Stevens GN, Bass PC, Tew P, Gebski VJ, Thompson JF, McCarthy WH (1997) Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma. Head Neck 19:589–594PubMed

62.

Hallemeier CL, Garces YI, Neben-Wittich MA, Olivier KR, Shon W, Garcia JJ, Brown, Foote RL (2013) Adjuvant hypofractionated intensity modulated radiation therapy after resection of regional lymph node metastases in patients with cutaneous malignant melanoma of the head and neck. Pract Radiat Oncol 3:e71–e77PubMed

63.

Shen P, Wanek LA, Morton DL (2000) Is adjuvant radiotherapy necessary after positive lymph node dissection in head and neck melanomas? Ann Surg Oncol 7:554–559 (discussion 60–61)PubMed

64.

Strojan P, Jancar B, Cemazar M, Perme MP, Hocevar M (2010) Melanoma metastases to the neck nodes: role of adjuvant irradiation. Int J Radiat Oncol Biol Phys 77:1039–1045PubMed

65.

Fuhrmann D, Lippold A, Borrosch F, Ellwanger U, Garbe C, Suter L (2001) Should adjuvant radiotherapy be recommended following resection of regional lymph node metastases of malignant melanomas? Br J Dermatology 144:66–70

66.

Negrier S, Saiag P, Guillot B, Verola O, Avril MF, Bailly C, Cupissol D, Dalac S, Danino A, Dreno B, Grob JJ, Leccia MT, Renaud-Vilmer C, Bosquet L (2005) National federation of cancer campaign C, french dermatology S. [Guidelines for clinical practice: standards, options and recommendations 2005 for the management of adult patients exhibiting an M0 cutaneous melanoma, full report. National federation of cancer campaign centers. French dermatology society. Update of the 1995 consensus conference and the 1998 standards, options, and recommendations]. Ann Dermatol Venereol 132:10S3–10S85PubMed

67.

Albarranweick M. Retrospektive Fall-Kontroll-Studie zum Stellenwert der adjuvanten Therapie des malignen Melanoms mit Iscador P.c.Hg. Dissertation, University Freiburg. 1998.

68.

Augustin M, Bock PR, Hanisch J, Karasmann M, Schneider B (2005) Safety and efficacy of the long-term adjuvant treatment of primary intermediate – to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented european mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland. Arzneimittel-Forschung 55:38–49PubMed

69.

Grossarth-Maticek R, Ziegler R (2007) Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador). Forsch Komplementarmed 14:140–147

70.

Grossarth-Maticek RZR (2007) Efficacy and safety of the long-term treatment of melanoma with a mistletoe preparation (Iscador). Schweiz Z Ganzheitsmed 19(6):325–332

71.

Kleeberg UR, Suciu S, Brocker EB, Ruiter DJ, Chartier C, Lienard D, Marsden J, Schadendorf D, Eggermont AM, Society EMGicwtGC (2004) Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 40:390–402PubMed

72.

Petrella TVS, Spithoff K, Quirt I, McCready D (2009) Systemic adjuvant therapy for patients at high risk for recurrent melanoma: updated guideline recommendations 2009. Cancer Care Ontario. Evidence-based series 8-1, Version 4. https://www.cancercare.on.ca

73.

Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM (2011) Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16:5–24PubMedCentralPubMed

74.

Grob JJ, Dreno B, de la Salmoniere P, Delaunay M, Cupissol D, Guillot B, Souteyrand P, Sassolas B, Cesarini JP, Lionnet S, Lok C, Chastang C, Bonerandi JJ (1998) Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 351:1905–1910PubMed

75.

Lens MB, Dawes M (2002) Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 20:1818–1825PubMed

76.

Mocellin S, Pasquali S, Rossi CR, Nitti D (2010) Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 102:493–501PubMed

77.

Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, Pachinger W, Aubock J, Fritsch P, Kerl H, Wolff K (1998) Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 16:1425–1429PubMed

78.

Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N (2006) Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 106:1431–1442PubMed

79.

Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S (2003) Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29:241–252PubMed

80.

Brand CU, Ellwanger U, Stroebel W, Meier F, Schlagenhauff B, Rassner G, Garbe C (1997) Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 79:2345–2353PubMed

81.

Leo F, Cagini L, Rocmans P, Cappello M, Geel AN, Maggi G, Goldstraw P, Pastorino U (2000) Lung metastases from melanoma: when is surgical treatment warranted? Br J Cancer 83:569–572PubMedCentralPubMed

82.

Sanki A, Scolyer RA, Thompson JF (2009) Surgery for melanoma metastases of the gastrointestinal tract: indications and results. Eur J Surg Oncol 35:313–319PubMed

83.

Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, Group B-S (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516PubMedCentralPubMed

84.

Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr., Kaempgen E, Martin-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358–365PubMed

85.

Leiter U, Buettner PG, Eigentler TK, Forschner A, Meier F, Garbe C (2010) Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit? Melanoma Res 20:240–246PubMed

86.

Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK (2011) KIT as a therapeutic target in metastatic melanoma. Jama 305:2327–2334PubMedCentralPubMed

87.

Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lin X, Du N, Zhang X, Li J, Wang B, Qin S (2011) Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 29:2904–2909PubMed

88.

Leiter U, Meier F, Garbe C (2014) Targeted therapies for melanoma. Hautarzt 65:600–606PubMed

89.

Hersh EM, O’Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS (2011) A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Investig New Drugs 29:489–498

90.

Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723PubMedCentralPubMed

91.

Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr., Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526PubMed

92.

McDermott D, Lebbe C, Hodi FS, Maio M, Weber JS, Wolchok JD, Thompson JA, Balch CM (2014) Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev 40:1056–1064PubMed

93.

Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, Cykowski L, de Pril V, Humphrey R, Lebbe C (2013) Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 24:2174–2180PubMedCentralPubMed

94.

Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saiag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22:1118–1125PubMed

95.

Bedikian AY, DeConti RC, Conry R, Agarwala S, Papadopoulos N, Kim KB, Ernstoff M (2011) Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol 22:787–793PubMedCentralPubMed

96.

Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG (2006) Oblimersen Melanoma Study G. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24:4738–4745PubMed

97.

Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745–2751PubMed

98.

Chauvergne J, Bui NB, Cappelaere P, Gary-Bobo J, Guerrin J, Armand JP, Durand M (1982) Chemotherapy in advanced malignant melanoma. Results of a controlled trial comparing a combination of dacarbazine (DTIC) and detorubicin with dacarbazine alone. Sem Hopitaux 58:2697–2701

99.

Kefford RF, Clingan PR, Brady B, Ballmer A, Morganti A, Hersey P (2010) A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. Mol Cancer 9:69PubMedCentralPubMed

100.

McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E (2008) Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 26:2178–2185PubMed

101.

Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158–166PubMed

102.

O’Day S, Pavlick A, Loquai C, Lawson D, Gutzmer R, Richards J, Schadendorf D, Thompson JA, Gonzalez R, Trefzer U, Mohr P, Ottensmeier C, Chao D, Zhong B, de Boer CJ, Uhlar C, Marshall D, Gore ME, Lang Z, Hait W, Ho P, Investigators C (2011) A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer 105:346–352PubMedCentralPubMed

103.

Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, Trefzer U, Punt CJ, Dummer R, Davidson N, Becker J, Conry R, Thompson JA, Hwu WJ, Engelen K, Agarwala SS, Keilholz U, Eggermont AM, Spatz A, Group EM (2011) Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer 47:1476–1483PubMed

104.

Ringborg U, Rudenstam CM, Hansson J, Hafstrom L, Stenstam B, Strander H (1989) Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study. Med Oncol Tumor Pharmacother 6:285–289PubMed

105.

Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Brocker EB, Grabbe S, Rittgen W, Edler L, Sucker A, Zimpfer-Rechner C, Berger T, Kamarashev J, Burg G, Jonuleit H, Tuttenberg A, Becker JC, Keikavoussi P, Kampgen E, Schuler G, DeCOG DCsgot (2006) Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17:563–570PubMed

106.

Thomson DB, Adena M, McLeod GR, Hersey P, Gill PG, Coates AS, Olver IN, Kefford RF, Lowenthal RM, Beadle GF et al (1993) Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res 3:133–138PubMed

107.

Weber JS, Amin A, Minor D, Siegel J, Berman D, O’Day SJ (2011) Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res 21:530–534PubMed

108.

Young AM, Marsden J, Goodman A, Burton A, Dunn JA (2001) Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clin Oncol 13:458–465

109.

Carter RD, Krementz ET, Hill GJ 2nd, Metter GE, Fletcher WS, Golomb FM, Grage TB, Minton JP, Sparks FC (1976) DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065). Cancer Treat Reports 60:601–609

110.

Chiarion Sileni V, Nortilli R, Aversa SM, Paccagnella A, Medici M, Corti L, Favaretto AG, Cetto GL, Monfardini S (2001) Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res 11:189–196PubMed

111.

Eigentler TK, Caroli UM, Radny P, Garbe C (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4:748–759PubMed

112.

Luikart SD, Kennealey GT, Kirkwood JM (1984) Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol 2:164–168PubMed

113.

Moon JH, Gailani S, Cooper MR, Hayes DM, Rege VB, Blom J, Falkson G, Maurice P, Brunner K, Glidewell O, Holland JF (1975) Comparison of the combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and vincristine with two dose schedules of 5-(3,3-dimethyl-1-triazino) imidazole 4-carboxamide (DTIC) in the treatment of disseminated malignant melanoma. Cancer 35:368–371PubMed

Titel: Maligne Melanome im Kopf-Hals-Bereich
Teil 2: Therapie
verfasst von: Prof. Dr. C. Pföhler
T. Vogt
C.S.L. Müller
Publikationsdatum: 01.08.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: HNO / Ausgabe 8/2015
Print ISSN: 0017-6192
Elektronische ISSN: 1433-0458
DOI: https://doi.org/10.1007/s00106-015-0034-5

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Maligne Melanome im Kopf-Hals-Bereich

Teil 2: Therapie

Zusammenfassung

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2015

Honorararzt – Konsiliararzt – Wahlarzt – Belegarzt – Kooperationsarzt

Hamartome im Kopf-Hals-Bereich

Höranstrengung bei Cochlea-Implantaten

Stationäre Rehabilitationsmaßnahmen bei erwachsenen CI-Trägern

Obliteration von Mastoidhöhlen

Prä- und Post-Ergebnisse einer stationären neurootologisch fundierten und psychosomatischen Tinnitustherapie

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO